ARVO Annual Meeting, Vancouver, BC, Canada

GenSight Biologics reports sustained quality of life improvements at Week 72 of Phase III REVERSE clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics enrolls first subject in first-in-man PIONEER Phase I/II clinical trial of GS030 combining gene therapy and Optogenetics for the treatment of Retinitis Pigmentosa

GenSight Biologics reports positive 72-week data from REVERSE Phase III clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics to present REVERSE data with GS010 at the 2018 Annual Meeting of the American Academy of Ophthalmology

GenSight Biologics provides an update on the clinical and regulatory pathways for GS010

GenSight Biologics reports positive additional data from REVERSE Phase III clinical trial of GS010 for treatment of Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics to Host KOL Event on June 12, 2018 in New York City

GenSight Biologics to Present Data on GS010 and GS030 at the Annual Meeting of ARVO

GenSight Biologics reports €49 million cash position as of March 31, 2018 and provides update on GS010